![Raymond Sanchez](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Raymond Sanchez
Directeur/Membre du Conseil chez
RAPPORT THERAPEUTICS, INC.
Fortune : - $ au 31/05/2026
Profil
Actuellement, Raymond Sanchez occupe le poste de directeur médical de Cerevel Therapeutics Holdings, Inc. Il est également membre du conseil d'administration de la Connecticut Mental Health Center Foundation et coprésident exécutif de l'International Society for CNS Drug Development. Dans sa carrière antérieure, il a occupé le poste de directeur médical chez Avanir Pharmaceuticals, Inc. Raymond Sanchez a obtenu un diplôme de premier cycle à l'université Northwestern et un doctorat à l'école de médecine Feinberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Raymond Sanchez
| Sociétés | Poste | Début |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/11/2024 |
| ALTO NEUROSCIENCE, INC. | Directeur/Membre du Conseil | 13/08/2025 |
Connecticut Mental Health Center Foundation | Directeur/Membre du Conseil | - |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | - |
Bain Capital Life Sciences LP
 Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Private Equity Investor | 01/09/2024 |
Anciens postes connus de Raymond Sanchez
| Sociétés | Poste | Fin |
|---|---|---|
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2024 |
International Society for CNS Drug Development
 International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Président | 01/01/2022 |
| AVANIR PHARMACEUTICALS INC | Directeur Technique/Scientifique/R&D | 01/01/2019 |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Corporate Officer/Principal | 01/01/2019 |
Formation de Raymond Sanchez
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Society for CNS Drug Development
International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Commercial Services |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Feinberg School of Medicine
 Feinberg School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Finance |
Cerevel Therapeutics Holdings, Inc.
 Cerevel Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel therapies for neurological and psychiatric disorders | Health Technology |
Connecticut Mental Health Center Foundation | |
Alto Neuroscience, Inc.
 Alto Neuroscience, Inc. BiotechnologyHealth Technology Engages in psychiatric drug development | Health Technology |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
Choisissez Zonebourse 
